Acrongenomics Inc. Nano-JETA Real Time PCR Against 'Gold Standard' Real Time PCR.

ATHENS, Greece -- Currently, molecular diagnostics market needs fast, personalized diagnosis, easy to handle methods, decreased cost and fast therapy decision without compromise in accuracy and reliability. Once these needs are covered a clear increase in growth rate of molecular diagnostics is expected. PCR applications in particular will reveal double-digit growth having the biggest share since PCR remains the workhorse for molecular genetic analysis.

Acrongenomics Inc. (OTCBB:AGNM) is currently conducting a clinical comparison study of its Nano-JETA(TM) Real Time PCR against the "gold standard", the common Real Time PCR technology, via the detection of Ep-CAM, HER1, HER2, vEGF and beta-actin genes in peripheral blood samples of 500 patients suffering from breast, colon, lung and ovarian cancer.

The objective of the study is to evaluate and compare the Nano-JETA(TM) Real Time PCR technology against the "gold standard" Real Time PCR protocols in regards to stability, sensitivity, specificity, reproducibility and compatibility by using three different types of Real Time PCR equipment to perform the Nano-JETA(TM) Real Time PCR application:

a) iCycler(TM) Real-Time PCR

b) Chromo4(TM) Real-Time PCR

c) Light cycler(TM) Real Time PCR

The study has been designed intentionally to incorporate the most difficult parameters such as blind control, multi-centre with variant and unidentified patient status (primary or metastatic status, follow up or on treatment).

Acrongenomics Inc. is a Research and Development company focusing in the field of Nanobiotechnology and has reshaped key IVD molecular applications such as PCR, ELISA and Real Time PCR through its Nano-JETA(TM) technology platform, by integrating nanotechnology into molecular biology.